Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:37 PM
Ignite Modification Date:
2025-12-24 @ 3:37 PM
NCT ID:
NCT04021992
Eligibility Criteria:
Inclusion Criteria:
* biopsy proved CD20+ DLBCL;
* previously received at least one systemic treatment (including chemotherapy) without remission or relapse after remission;
* at least one evaluable lesion；
* ECOG PS 0-1;
* 18-65 years;
* proper functioning of the major organs.
Exclusion Criteria:
* involvement of central nervous system;
* with other malignancy;
* patients receiving or received drug of other clinical trial within 30 days；
* previously received doxorubicin liposome or have used other anthracycline drug with accumulated restricted doses (adriamycin 450mg/m2, epirubicin 935mg/m2, acrarubicin 900mg/m2)；
* patients who received treatment for hematologic toxicity caused by previous chemotherapy within 7 days before enrollment;
* grade 2 or more peripheral neuropathy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT04021992
Study Brief:
Protocol Section:
NCT04021992